参考文献/References:
[1]Farmakis D,Chrysohoou C,Giamouzis G,et al. The management of atrial fibrillation in heart failure:an expert panel consensus[J]. Heart Fail Rev,2020,May 28.DOI:10.1007/s10741-020-09978-0.Epub ahead of print.
[2]Santhanakrishnan R,Wang N,Larson MG,et al. Atrial fibrillation begets heart failure and vice versa:temporal associations and differences in preserved versus reduced ejection fraction[J]. Circulation,2016,133(5):484-492.
[3] Zafrir B,Lund LH,Laroche C,et al. Prognostic implications of atrial fibrillation in heart failure with reduced,mid-range,and preserved ejection fraction:a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry[J]. Eur Heart J,2018,39(48):4277-4284.
[4]Stafylas P,Farmakis D,Kourlaba G,et al. The heart failure pandemic:the clinical and economic burden in Greece[J]. Int J Cardiol,2017,227:923-929.
[5]Kartas A,Samaras A,Vasdeki D,et al. Flaws in anticoagulation strategies in patients with atrial fibrillation at hospital discharge[J]. J Cardiovasc Pharmacol Ther,2019,24(3):225-232.
[6]Savarese G,Giugliano RP,Rosano GM,et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure:a meta-analysis[J]. JACC Heart Fail,2016,4(11):870-880.
[7]Cheng M,Lu X,Huang J,et al. The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function:insights from a meta-analysis[J]. Eur J Heart Fail,2014,16(12):1317-1322.
[8]Zhao L,Wang WYS,Yang X. Anticoagulation in atrial fibrillation with heart failure[J]. Heart Fail Rev,2018,23(4):563-571.
[9]Verma A,Kalman JM,Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction[J]. Circulation,2017,135(16):1547-1563.
[10]Wyse DG,van Gelder IC,Ellinor PT,et al. Lone atrial fibrillation:does it exist?[J]. J Am Coll Cardiol,2014,63(17):1715-1723.
[11]Guichard JB,Nattel S. Atrial cardiomyopathy:a useful notion in cardiac disease management or a passing fad?[J]. J Am Coll Cardiol,2017,70(6):756-765.
[12]Schotten U,Dobrev D,Platonov PG,et al. Current controversies in determining the main mechanisms of atrial fibrillation[J]. J Intern Med,2016,279(5):428-438.
[13]Mueller C,McDonald K,de Boer RA,et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations[J]. Eur J Heart Fail,2019,21(6):715-731.
[14]Pieske B,Tsch?pe C,de Boer RA,et al. How to diagnose heart failure with preserved ejection fraction:the HFA-PEFF diagnostic algorithm:a consensus recommendation from the Heart Failure Association(HFA) of the European Society of Cardiology(ESC)[J]. Eur Heart J,2019,40(40):3297-3317.
[15]Wijesurendra RS,Casadei B. Seek and Ye Shall find subclinical atrial fibrillation in high-risk elderly patients[J]. Circulation,2017,136(14):1284-1287.
[16]Kotecha D,Flather MD,Altman DG,et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure[J]. J Am Coll Cardiol,2017,69(24):2885-2896.
[17]Filippatos G,Farmakis D. How to use beta-blockers in heart failure with reduced ejection fraction and atrial fibrillation[J]. J Am Coll Cardiol,2017,69(24):2897-2900.
[18]Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace,2016,18(11):1609-1678.
[19]Roy D,Talajic M,Nattel S,et al. Rhythm control versus rate control for atrial fibrillation and heart failure[J]. N Engl J Med,2008,358(25):2667-2677.
[20]Prabhu S,Taylor AJ,Costello BT,et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction:the CAMERA-MRI study[J]. J Am Coll Cardiol,2017,70(16):1949-1961.
[21]di Biase L,Mohanty P,Mohanty S,et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device:results from the AATAC multicenter randomized trial[J]. Circulation,2016,133(17):1637-1644.
[22]Khan MN,Jais P,Cummings J,et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure[J]. N Engl J Med,2008,359(17):1778-1785.
[23]Marrouche NF,Brachmann J,Andresen D,et al. Catheter ablation for atrial fibrillation with heart failure[J]. N Engl J Med,2018,378(5):417-427.
[24]Chen S,Purerfellner H,Meyer C,et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation:a stratified pooled analysis of randomized data[J]. Eur Heart J,2020,41(30):2863-2873.
[25]Packer DL,Mark DB,Robb RA,et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality,stroke,bleeding,and cardiac arrest among patients with atrial fibrillation:the CABANA randomized clinical trial[J]. JAMA,2019,321(13):1261-1274.
[26]Gopinathannair R,Etheridge SP,Marchlinski FE,et al. Arrhythmia-induced cardiomyopathies:mechanisms,recognition,and management[J]. J Am Coll Cardiol,2015,66(15):1714-1728.
[27]Richter S,di Biase L,Hindricks G. Atrial fibrillation ablation in heart failure[J]. Eur Heart J,2019,40(8):663-671.
[28]Cleland JGF,Bunting KV,Flather MD,et al. Beta-blockers for heart failure with reduced,mid-range,and preserved ejection fraction:an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J,2018,39(1):26-35.
[29]McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[30]Bohm M,Slawik J,Brueckmann M,et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation:data from the EMPA-REG OUTCOME trial[J]. Eur J Heart Fail,2020,22(1):126-135.
[31]Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975.
[32]Tang AS,Wells GA,Talajic M,et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure[J]. N Engl J Med,2010,363(25):2385-2395.
[33]Moss AJ,Schuger C,Beck CA,et al. Reduction in inappropriate therapy and mortality through ICD programming[J]. N Engl J Med,2012,367(24):2275-2283.